pcf-39 and Adenocarcinoma

pcf-39 has been researched along with Adenocarcinoma* in 1 studies

Other Studies

1 other study(ies) available for pcf-39 and Adenocarcinoma

Article	Year
In vitro and in vivo immunomodulatory activity of an N-9 arginyl hypoxanthine derivative (PCF-39). International journal of immunopharmacology, 1987, Volume: 9, Issue:6 A new synthetic derivative, N-alpha-5 (1,6-dihydro-6-oxo-9-purinyl) pentyloxy-carbonyl-L-arginine (PCF-39) has been evaluated in vitro and in vivo in order to clarify its immunopharmacologic profile. In vitro, PCF-39 did not modify spleen cell functions, whereas parenteral administration in mice of 2.5 and 25 mg/kg (50 and 500 micrograms/mouse) induced an increase in spleen and lymph node cellularity that resulted in a significant resistance to the growth of two distinct syngeneic transplanted tumors. These in vivo findings show that PCF-39 is a potent immunotherapeutic agent with an antitumor effect. Topics: Adenocarcinoma; Animals; Arginine; Cell Cycle; Female; Hypoxanthines; Killer Cells, Natural; Leukocyte Count; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Spleen	1987

Article

Year

In vitro and in vivo immunomodulatory activity of an N-9 arginyl hypoxanthine derivative (PCF-39).

International journal of immunopharmacology, 1987, Volume: 9, Issue:6

A new synthetic derivative, N-alpha-5 (1,6-dihydro-6-oxo-9-purinyl) pentyloxy-carbonyl-L-arginine (PCF-39) has been evaluated in vitro and in vivo in order to clarify its immunopharmacologic profile. In vitro, PCF-39 did not modify spleen cell functions, whereas parenteral administration in mice of 2.5 and 25 mg/kg (50 and 500 micrograms/mouse) induced an increase in spleen and lymph node cellularity that resulted in a significant resistance to the growth of two distinct syngeneic transplanted tumors. These in vivo findings show that PCF-39 is a potent immunotherapeutic agent with an antitumor effect.

Topics: Adenocarcinoma; Animals; Arginine; Cell Cycle; Female; Hypoxanthines; Killer Cells, Natural; Leukocyte Count; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Spleen

1987